Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 2 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready • 3 patents granted in the last 365 days
BioTheryX Inc. has 3 pending office actions in the Biotechnology & Pharmaceuticals technology area. These matters are spread across 3 distinct examiners and 2 distinct art units, showing some concentration within the art units despite the involvement of multiple examiners. This suggests that while the technical field is somewhat focused, the individual reviewers vary across the portfolio.
WILLIS, DOUGLAS M is the busiest examiner for the company, handling 1 busiest examiner pending office action. The portfolio's 3 pending actions are split among different examiners, necessitating separate management for each application. Although there are 3 distinct examiners, they are operating within only 2 distinct art units, which may provide some consistency in the broader technical guidelines applied to the cases.
The presence of 3 pending office actions in the biotechnology sector requires a careful approach to examiner interaction. Since each action is assigned to a different person, the applicant cannot rely on a single relationship to move the portfolio forward. However, the concentration in 2 distinct art units may allow for some shared insights into the prior art landscape that the USPTO is currently prioritizing for these pharmaceutical innovations.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (33%) |
| Double-patenting + other | 1 (33%) |
| Multi-statute (no §101) | 1 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| WILLIS, DOUGLAS M | 1 | 82.4% | +19.7% |
| HUI, SAN MING R | 1 | 59.5% | +20.1% |
| WHITE, DAWANNA SHAR-DAY | 1 | 62.5% | +23.3% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18626823 | INDAZOLES, PHARMACEUTICAL COMPOSITIONS, AND THERAPEUTIC APPLICATIONS | WILLIS, DOUGLAS M | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18245125 | SOS1 PROTEIN DEGRADERS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR THERAPEUTIC APPLICATIONS | WHITE, DAWANNA SHAR-DAY | 12d |
| 18626823 | INDAZOLES, PHARMACEUTICAL COMPOSITIONS, AND THERAPEUTIC APPLICATIONS | WILLIS, DOUGLAS M | — |
| 18552482 | KRAS PROTEIN DEGRADERS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR THERAPEUTIC APPLICATIONS | HUI, SAN MING R | — |
| Art Unit | Apps |
|---|---|
| 1627 | 2 |
| 1624 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18626823 | INDAZOLES, PHARMACEUTICAL COMPOSITIONS, AND THERAPEUTIC APPLICATIONS | WILLIS, DOUGLAS M | 1624 | §102§112 | Non-Final OA | — | Pending | Apr 04, 2024 |
| 18552482 | KRAS PROTEIN DEGRADERS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR THERAPEUTIC APPLICATIONS | HUI, SAN MING R | 1627 | §103 | Non-Final OA | — | Pending | Sep 26, 2023 |
| 18245125 | SOS1 PROTEIN DEGRADERS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR THERAPEUTIC APPLICATIONS | WHITE, DAWANNA SHAR-DAY | 1627 | §103DP | Non-Final OA | 12d | Pending | Mar 13, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial